Given a paragraph and a claim, classify it this way: If the claim contradicts the evidence present in the paragraph, classify the claim as '0'. If the claim has multiple supporting *AND* contradicting evidences, classify the claim as '1'. If the claim has supporting evidence and the paragraph is in overall favor of the claim, then classify the claim as '2'.

Input: Consider Input: Paragraph: Such hedge funds, often cast as villains of the piece because they bet against share prices, scent a profit from company valuations they believe are unduly inflated by ESG promises or which they say ignore risks that threaten to undermine the company's prospects. The fact short-sellers, who look to exploit information gaps, are targeting the ESG sphere underlines the complexities facing investors in accurately gauging companies' sustainability credentials. Teenage climate activist Greta Thunberg last week spoke of CEOs masking inaction with "creative PR". Against a backdrop of growing public and political concerns about climate change and economic inequality, companies are under increasing pressure to show they are taking greater responsibility for how they generate their profits. Investments defined as "sustainable" account for more than a quarter of all assets under management globally, according to the Global Sustainable Investment Alliance. About $31 trillion has been invested, buoyed by analyst reports that show companies with strong ESG narratives outperform their peers. Some short-sellers, including Carson Block of Muddy Waters, Josh Strauss of Appleseed Capital and Chad Slater of Morphic Asset Management, argue share prices can be bolstered by corporate misrepresentation about sustainability, or so-called "greenwashing". "Greenwashing is absolutely rampant now," says Slater, whose fund bets on both rising and falling share prices. If companies fail to engage with long-term investors, he sees a red flag. "From the short side, it's quite interesting." Analytics companies that provide corporate ESG ratings use a combination of company disclosures, news sources and qualitative analysis of third-party data. They are a major source of information for investors, but it is not an exact science. Hedge funds have various strategies for selecting targets, often focusing on those they think show both ESG and more traditional financial or operational weakness. A high ESG rating can attract short interest. A Reuters analysis of data from financial information company Refinitiv and national regulators in Britain, France, Germany, Spain and Italy shows the five companies in each country with the best ESG scores collectively were being shorted more than those with the worst scores. The short positions against the companies deemed to have the best ESG credentials were 50% greater in size than those placed against the worst-performers. (Graphic: ESG shorts - UK: here) For an interactive version of the graphic, click here tmsnrt.rs/2RwpBDj. For additional graphics covering the other countries mentioned, see related content. ESG data providers compile ratings based on a slew of measures ranging from energy usage to board gender make-up, salary gap data and the scale of negative press reports on the company from newspapers across the world. Refinitiv, part-owned by the parent company of Reuters News, factors in more than 400 ESG measures for each company, taken from a range of sources including company reports, regulatory filings, NGO websites and news articles. A key problem, though, is scant regulations governing what ESG measures and risks companies must disclose and their patchy nature, said Diederik Timmer, executive vice president of client relations at Sustainalytics, a major ESG data provider. "When things go well, companies report quite well on those, when things don't go so well it gets awfully quiet," he added. Some policymakers, largely in Europe, are pushing for standardized disclosures to help investors better gauge the risks, something which will leave less wriggle room for companies and make scores even more reliable. Two leading global asset managers interviewed by Reuters, who manage nearly $1 trillion in assets but declined to be identified, said they had tested their portfolios using several data providers and found the correlation between ESG ratings to be so low, they are building their own ranking system. Peter Hafez, chief data scientist at RavenPack, which helps hedge funds analyze data to get a trading edge, agreed. "There's no perfect ESG rating out there," he said. The influence of news flows on investor sentiment was underlined by a Deutsche Bank study here published in September that mapped 1,600 stocks and millions of company announcements and climate-related media reports over two decades. It found companies that had a greater proportion of positive announcements and press over the preceding 12 months outperformed the MSCI World Index by 1.4% a year, on average, while those with more negative news underperformed by 0.3%. For graphics of the data, click here tmsnrt.rs/2ncsFY0 and here tmsnrt.rs/2nd5hcT. Short-sellers borrow shares, pay the lender a fee and sell them on, betting the price will fall before buying them back and returning them to the original lender - pocketing the difference, minus the fee. But it is not for the faint-hearted. If funds trigger a share price fall, they can earn millions, but the downside, should shares rise, is unlimited. The perils of the practice were shown by the shorts burnt by a 17% surge in the shares of Elon Musk's Tesla (TSLA.O) in October after a surprise quarterly profit. Short-sellers suffered paper losses of $1.4 billion, erasing most of their 2019 profits, according to analytics firm S3 Partners. And in a decade-long stock market bull-run, short-selling can be tricky. Morphic's joint chief investment officer Slater said the Sydney-based money manager's standalone short positions in its Trium Morphic ESG long-short fund had weighed on the portfolio over the past 12 months. Niche activist short-sellers, who can torpedo company valuations by publishing negative reports on targets - often alleging fraud or serious failures - are often criticized for undermining long-term company objectives and blurring the lines between whistleblower and market manipulator. Short-sellers agree they are biased, but argue no more than long investors, the banks that raise money for the company and the company's management. Carson Block, founder of American short-seller Muddy Waters, who shot to prominence spotting wrongdoing in some Chinese-run companies, is now seeking a "morality short" on ESG - branching out from a traditional focus on corporate governance issues to targets whose success he says hinges on secretly harming society. As an example of what he is seeking, he points to the U.S. opioid crisis, which has triggered around 2,500 lawsuits by authorities seeking to hold drugmakers responsible for stoking a scandal that has claimed almost 400,000 overdose deaths between 1999 and 2017. "I'm really skeptical of ESG," he says, likening the use of the acronym by the corporate world to the token straw slipped into a large plastic cup with a plastic lid. "ESG is the paper straw of investing," he says. "I definitely want to find companies like that because I know they're out there and I want to help put them down." Claim: Villains or visionaries? Hedge funds short companies they say 'greenwash'.

Output: 2

Input: Consider Input: Paragraph: Frates is fighting back from a summer health scare that landed him in the hospital while still trying to be a public face of amyotrophic lateral sclerosis, or ALS, a degenerative disease that destroys nerve cells, impairs physical functions and so far has no cure. The former Boston College baseball star, who can no longer speak or move, spent most of July in the hospital battling pneumonia and other infections. In July, a tweet erroneously reporting his demise led to worldwide headlines. Frates wryly countered by posting a short video of himself lying in a hospital bed with Pearl Jam's "Alive" playing in the background. Using a computer system that lets him type out words through eye movements, Frates has been tweeting about his progress to his nearly 30,000 followers, along with regular musings about his family and friends, living with ALS and Boston sports. "lots of down days as you can imagine with als, sometimes you don't feel human," he tweeted Sept. 23. "Today I am definitely feeling sorry for myself, sukxx. but I will bounce back. Eff! you als.. Friggin a hole! !" In the weeks since his July health scare, the 32-year-old has re-emerged to accept honors and accolades across his home state of Massachusetts. Last month, he joined Boston Mayor Marty Walsh, Red Sox officials and the Boston College baseball team on the steps of City Hall to declare Sept. 5 "Pete Frates Day" in Boston. And former Red Sox slugger David Ortiz and other Boston sports legends feted Frates at Fenway Park to mark the release of a new book on his life, "The Ice Bucket Challenge: Pete Frates and the Fight Against ALS." Half the proceeds benefit Frates and his family. Frates' wife, Julie, said it's been a difficult and busy few months, but she couldn't persuade her husband to slow things down even if she wanted to. "He's the one pushing to be out there," she said. "We take all the lead from him." The ice bucket challenge had been around for almost a year to benefit various causes. But Frates is credited with helping focus it on ALS specifically and taking it global using his wide network of supporters as an established ALS advocate. The challenge raised roughly $220 million in 2014, of which $115 million went to the ALS Association. A sequel campaign the next summer raised just over $1 million, according to the association. The ALS Association says it has committed more than $89 million of the 2014 windfall to research. "New, exciting research is just starting to pan out, and that's drawing new talent to ALS research, and a lot of companies are now interested in ALS," said Dr. Nazem Atassi, a Massachusetts General Hospital neurologist whose ALS research benefited from ice bucket challenge money. "It's the perfect environment for drug discovery." Among the most promising developments to come out of research funded by the challenge has been the identification of at least four genes that contribute to the disease, a critical step toward developing new treatments, said Kevin Eggan, a professor at Harvard University who specializes in ALS. Another development that gives the Frates family hope is Radicava, a drug approved in May by the U.S. Food and Drug Administration following testimony from the Frates and other advocates. It's the first new treatment approved specifically for ALS in 22 years. Frates' mother, Nancy, said they're applying to get her son on the drug, even though it's not clear how it might help, given his advanced condition. The medication, which was developed in Japan without funding from the ice bucket challenge, has been shown to slow the disease in recently diagnosed patients. "You just want it to stop," Nancy said. "You want someone to say this disease is not tearing through your loved one's body anymore." ALS is still finding new ways to attack Frates, said his father, John, a city councilor in Beverly who quit his financial services job to help care for his son after he was diagnosed in 2012. Frates' bladder stopped working last year, requiring his urine now to be drained with a catheter every three hours, John Frates said. "It's amazing he's tolerating all of it. It just shows the courage, will and determination he has to be with us," Frates' father said. "He's as incapacitated as a human being can be. That's his quality of life." ___ Follow Philip Marcelo at twitter.com/philmarcelo. His work can be found at https://www.apnews.com/search/philip%20marcelo Claim: ALS patient behind ice bucket challenge: I will bounce back.

Output: 2

Input: Consider Input: Paragraph: The Missouri Department of Health and Senior Services announced the winning applicants Thursday, just days after the state awarded licenses to companies seeking to transport cannabis products. Testing facilities were licensed earlier this month, reports the St. Louis Post-Dispatch. The newly announced licensees included Blue Arrow Holdings LLC, a newly formed company that plans to retrofit a building in the long-shuttered Lempt Brewery complex in St. Louis to grow cannabis indoors, reports the St. Louis Post-Dispatch. "We'll be taking over that space and sustaining it," said Max Bonanno, a consultant to Blue Arrow Holdings. "It's pretty cool." But some of the applicants that didn't win licenses threatened to sue or appeal. Among them was Dr. Paul Callicoat, a retired cardiologist and a principal of Sarcoxie Nursery in southwest Missouri, who said his family will review "all available lawful remedies" to reverse this decision. Voters made medical marijuana legal in 2018. The licensing program is expected to wind up by February with the awarding of licenses to applicants seeking to sell cannabis products to Missourians holding doctor-approved cards. Claim: State awards license to grow medical marijuana in Missouri.
Output: 2